AQZ – Credit Suisse rates the stock as Outperform
The Outperform rating is retained and the target price decreases to $4.80 from $5.30.
Read MoreBroker News
NWS – UBS rates the stock as Buy
The broker raises FY22-24 EPS forecasts by 34%, 12% and 11%, respectively, which lifts the price target to $42.5 from $41.50.
Read MoreSUN – UBS rates the stock as Buy
The Buy rating is retained and the target price increases to $14.00 from $13.85.
Read MoreMQG – Credit Suisse rates the stock as Neutral
The Neutral rating is retained as earnings may be approaching peak levels, estimates the broker. The target price rises to $210 from $195.
Read MoreCLW – Macquarie rates the stock as Outperform
Outperform rating retained. Target price eases to $5.23 from $5.31.
Read MoreGUD – UBS rates the stock as Buy
The Buy rating is retained and the target price increases to $14.40 from $13.80.
Read MoreSCP – Credit Suisse rates the stock as Neutral
The broker raises its target price to $2.94 from $2.83. The Neutral rating is maintained.
Read MoreJHX – UBS rates the stock as Buy
UBS raises its target price for James Hardie by 5% to $58 following a “good” 3Q result and “solid” FY23 guidance. The Buy rating is unchanged.
Read MoreANZ – UBS rates the stock as Buy
Price target $30. Buy. UBS’s estimates are below market consensus.
Read MoreGNC – Credit Suisse rates the stock as Neutral
The Neutral rating is retained and the target price increases to $7.17 from $6.78.
Read MoreREA – Macquarie rates the stock as Neutral
The Neutral rating is maintained on downside risk to the consensus forecast in the medium term. The target price eases to $158 from $162.
Read MoreDMP – UBS rates the stock as Buy
UBS has again downgraded earnings for Domino Pizza Enterprises, cutting the target price -20% to $120 from $150. But it upgrades to Buy from Neutral to reflect the strident retreat in the share price from nearly $165 in September.
Read MoreBRG – Credit Suisse rates the stock as Neutral
The Neutral rating is retained and the target price decreases to $29.86 from $30.98.
Read MoreNUF – Credit Suisse rates the stock as Neutral
The Neutral rating is retained and the target price increases to $6.14 from $5.01.
Read MoreTWE – UBS rates the stock as Buy
Strengthening prices are particularly good news for the Penfolds brand, according to the broker. The Buy rating and $13.50 target price are maintained.
Read MoreTLS – Morgans rates the stock as Add
Morgans makes immaterial EPS forecast changes. The target price rises to $4.56 from $4.55 and the Add rating is maintained.
Read MoreCPU – UBS rates the stock as Buy
The rating is upgraded to Buy from Neutral and the target price increases to $22.50.
Read MoreCHC – Macquarie rates the stock as Outperform
Outperform and $22.68 target retained.
Read MoreCIP – Morgans rates the stock as Hold
Morgans retains its Hold rating and raises its target price to $4.12 from $4.09.
Read MoreARB – Macquarie rates the stock as Neutral
Neutral retained, traget rises to $49.30 from $46.00.
Read MoreIGO – Credit Suisse rates the stock as Outperform
The Outperform rating is retained and the target price decreases to $15.30 from $16.30.
Read MoreCTD – Morgans rates the stock as Add
Morgans target price rises to $29 from $27.36. The Add rating is unchanged.
Read MorePBH – Credit Suisse rates the stock as Neutral
Target falls to $5.50 from $8.00, downgrade to Neutral from Outperform.
Read MoreCBL – Morgans rates the stock as Add
The target price slips to $1.32 from $1.42 and the Speculative Buy rating is maintained, as the analyst expects several upcoming catalysts’s for a share price rally.
Read MoreFCL – Macquarie rates the stock as Outperform
Target price falls to $3.98 from $4.92 to reflect the recent shift in relative valuation and the broker is keeping a wary eye to new client acquisition. Outperform rating retained.
Read MoreCHN – Macquarie rates the stock as Outperform
Outperform rating and $10.55 target price retained.
Read MoreNCM – Morgans rates the stock as Add
The broker expects gold production and headline costs at Cadia to normalise in the 2H of 2022 and maintains its Add rating while easing its target price to $26.05 from $27.18.
Read MoreEVN – Credit Suisse rates the stock as Neutral
The broker adjusts its target price to $3.70 from $3.80 and maintains its Neutral rating.
Read MoreAMI – Macquarie rates the stock as Outperform
The broker has increased its target to 60c from 55c, Outperform retained.
Read MoreJIN – Morgans rates the stock as Add
The target price rises to $20.75 from $20.20 and the Add rating is maintained.
Read MoreALX – Morgans rates the stock as Add
The Add rating is retained and the target price rises to $6.91 from $6.78.
Read MoreALL – Credit Suisse rates the stock as Outperform
Outperform rating and $49 target price are retained.
Read MoreBPT – Macquarie rates the stock as Neutral
The broker maintains its Neutral rating and $1.40 target price.
Read MoreA2M – UBS rates the stock as Buy
The Buy rating and target price of NZ$10.20 are retained.
Read MoreDHG – Macquarie rates the stock as Neutral
The Neutral rating is retained and the target price increases to $4.90 from $4.80.
Read MoreADH – Morgans rates the stock as Add
The broker lowers its target price to $3.70 from $4.80. It’s thought the estimated FY23 price earnings ratio of 7.6x and currently attractive dividend yield are enough to retain an Add rating.
Read MoreSHL – Macquarie rates the stock as Neutral
The target price for Sonic Healthcare rises to $42.40 from $42.25 and the Neutral rating is maintained.
Read MoreWHC – Morgans rates the stock as Add
The analyst’s target price of $3.65 (down from $3.92) includes a premium to allow for upside risk for coal prices. Add rating maintained.
Read MoreSTO – Morgans rates the stock as Add
Morgans maintains its Add rating and suggests a large share price discount still exists with the potential for many positive catalysts in 2022. The target price rises to $9.15 from $8.65.
Read MoreNST – Credit Suisse rates the stock as Outperform
The broker reiterates the company is a preferred gold pick and raises its target price to $10.80 from $10.20. Outperform.
Read More
